Literature DB >> 1401748

Secretion of growth hormone releasing hormone in obese children.

S Loche1, S Balzano, M Bozzola, A Moretta, S Pintus, A Faedda, A Muntoni, D Carta, C Pintor.   

Abstract

We have evaluated baseline and l-dopa-stimulated peripheral growth hormone releasing hormone (pGHRH) secretion in 6 obese pre-pubertal children and in 7 age-matched controls. Baseline pGHRH levels were no different between obese (36.6 +/- 9.8 pg/ml, mean +/- SE) and control children (40.6 +/- 10.1 pg/ml). Administration of l-dopa (500 mg po) caused a significant increase of pGHRH levels in both the obese (65.3 +/- 19.8 pg/ml, p less than 0.05) and the control children (84.1 +/- 10.0 pg/ml, p less than 0.003). Mean peak pGHRH levels after l-dopa were not significantly different between the two groups, whereas mean peak GH levels were significantly lower (p less than 0.05) in the obese (7.9 +/- 1.9 ng/ml) than in the control children (20.5 +/- 4.9 ng/ml). We conclude that despite reduced GH secretion, obese children have normal baseline and l-dopa stimulated pGHRH levels.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1401748     DOI: 10.1007/BF03348770

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  30 in total

1.  L-dopa stimulates release of hypothalamic growth hormone-releasing hormone in humans.

Authors:  K Chihara; Y Kashio; T Kita; Y Okimura; H Kaji; H Abe; T Fujita
Journal:  J Clin Endocrinol Metab       Date:  1986-03       Impact factor: 5.958

2.  Variations of plasma growth hormone (GH)-releasing factor levels during GH stimulation tests in children.

Authors:  M Donnadieu; D Evain-Brion; M C Tonon; H Vaudry; J C Job
Journal:  J Clin Endocrinol Metab       Date:  1985-06       Impact factor: 5.958

3.  Reduced growth hormone response to growth hormone-releasing hormone in children with simple obesity: evidence for somatomedin-C mediated inhibition.

Authors:  S Loche; M Cappa; P Borrelli; A Faedda; A Crinò; S G Cella; R Corda; E E Müller; C Pintor
Journal:  Clin Endocrinol (Oxf)       Date:  1987-08       Impact factor: 3.478

4.  Effect of cholinergic enhancement by pyridostigmine on growth hormone secretion in obese adults and children.

Authors:  E Ghigo; E Mazza; A Corrias; E Imperiale; S Goffi; E Arvat; J Bellone; C De Sanctis; E E Müller; F Camanni
Journal:  Metabolism       Date:  1989-07       Impact factor: 8.694

5.  Effect of dietary restriction and repeated growth hormone-releasing factor injections on growth hormone response to growth hormone-releasing factor in obese subjects.

Authors:  I Csizmadi; P Brazeau; O Serri
Journal:  Metabolism       Date:  1989-10       Impact factor: 8.694

6.  Impaired growth hormone response to growth hormone releasing factor and insulin-hypoglycaemia in obesity.

Authors:  P G Kopelman; K Noonan; R Goulton; A J Forrest
Journal:  Clin Endocrinol (Oxf)       Date:  1985-07       Impact factor: 3.478

7.  Nocturnal release of immunoreactive growth hormone-releasing hormone and growth hormone in normal children.

Authors:  P Tapanainen; H Rantala; J Leppäluoto; P Lautala; M L Käär; M Knip
Journal:  Pediatr Res       Date:  1989-11       Impact factor: 3.756

8.  Circulating somatomedin-C levels and the effect of growth hormone-releasing factor on plasma levels of growth hormone and somatostatin-like immunoreactivity in obese children.

Authors:  R Rosskamp; M Becker; S Soetadji
Journal:  Eur J Pediatr       Date:  1987-01       Impact factor: 3.183

9.  Pyridostigmine counteracts the blunted growth hormone response to growth hormone-releasing hormone of obese children.

Authors:  S Loche; C Pintor; M Cappa; E Ghigo; R Puggioni; V Locatelli; E E Müller
Journal:  Acta Endocrinol (Copenh)       Date:  1989-05

10.  Stimulation by food of peripheral plasma immunoreactive growth hormone releasing factor.

Authors:  A M Sopwith; E S Penny; G M Besser; L H Rees
Journal:  Clin Endocrinol (Oxf)       Date:  1985-03       Impact factor: 3.478

View more
  4 in total

1.  GH/IGF-I axis in Prader-Willi syndrome: evaluation of IGF-I levels and of the somatotroph responsiveness to various provocative stimuli. Genetic Obesity Study Group of Italian Society of Pediatric Endocrinology and Diabetology.

Authors:  A Corrias; J Bellone; L Beccaria; L Bosio; G Trifirò; C Livieri; L Ragusa; A Salvatoni; M Andreo; P Ciampalini; G Tonini; A Crinò
Journal:  J Endocrinol Invest       Date:  2000-02       Impact factor: 4.256

2.  Impairment of GH responsiveness to GH-releasing hexapeptide (GHRP-6) in Prader-Willi syndrome.

Authors:  G Grugni; G Guzzaloni; F Morabito
Journal:  J Endocrinol Invest       Date:  2001-05       Impact factor: 4.256

3.  Growth hormone binding protein activity in obese children.

Authors:  S Seminara; A Filpo; F La Cauza; A Faedda; A Miola; S Pellizzone; M Casati; S Loche
Journal:  J Endocrinol Invest       Date:  1998 Jul-Aug       Impact factor: 4.256

4.  Endogenous growth hormone (GH)-releasing hormone is required for GH responses to pharmacological stimuli.

Authors:  C A Jaffe; R DeMott-Friberg; A L Barkan
Journal:  J Clin Invest       Date:  1996-02-15       Impact factor: 14.808

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.